AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:27 2024-06-18 am EDT			5-day change	1st Jan Change
12,416 ^GBX	-0.10%		+0.32%	+17.13%

05:25pm	Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...
01:20pm	ASTRAZENECA : Goldman Sachs maintains a Buy rating	ZD

AstraZeneca : Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria

July 26, 2021 at 02:08 am EDT

Opinion based on results from Ultomiris Phase III trial that showed an established efficacy and safety profile with reduced treatment burden for children with PNH and their families

Attachments

Original document
Permalink

Disclaimer

AstraZeneca plc published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 06:07:03 UTC.

Latest news about AstraZeneca PLC

Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...	11:25am
ASTRAZENECA : Goldman Sachs maintains a Buy rating	07:20am	ZD
AstraZeneca disappointed by breast cancer drug trial results	04:34am	AN
London follows US bullish trend	04:02am
AstraZeneca: inconclusive trial in breast cancer	03:54am	CF
AstraZeneca's Breast Cancer Combo Fails to Extend Overall Survival in Late-stage Trial	03:10am	MT
UK Stocks-Factors to watch on June 18	03:08am	RE
Ashtead profit declines; Whitbread sales rise	02:52am	AN
AstraZeneca's breast cancer drug combination fails in late-stage trial	02:52am	RE
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals	02:39am	DJ
European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov	Jun. 17	MT
Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco...	Jun. 17
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer	Jun. 17	MT
AstraZeneca: positive phase 3 results in lymphoma	Jun. 17	CF
AstraZeneca's Blood Cancer Combination Therapy Meets Primary Goal in Late-Stage Study	Jun. 17	MT
London stocks rebound ahead of key Economic data	Jun. 17
Astra's Imfinzi plus chemo approved for cancer form in US	Jun. 17	AN
AstraZeneca: Imfinzi approved in endometrial cancer	Jun. 17	CF
Astra gets US drug approval; Ascential trades in line	Jun. 17	AN
AstraZeneca Gains US FDA Approval for Endometrial Cancer Treatment	Jun. 17	MT
UK Stocks-Factors to watch on June 17	Jun. 17	RE
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer	Jun. 17	DJ
AstraZeneca gets positive cancer test results for Calquence	Jun. 17	AN
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer	Jun. 17	RE
AstraZeneca's Calquence Combo Extends Progression-free Survival in Mantle Cell Lymphoma Study	Jun. 17	MT

Chart AstraZeneca PLC

Duration

Period

More charts

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

157.7 USD

Average target price

174.4 USD

Spread / Average Target

+10.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+17.13%	244B
ELI LILLY AND COMPANY	+52.41%	797B
NOVO NORDISK A/S	+40.55%	628B
JOHNSON & JOHNSON	-7.14%	351B
MERCK & CO., INC.	+17.24%	323B
ABBVIE INC.	+10.71%	300B
ROCHE HOLDING AG	+1.39%	223B
AMGEN INC.	+6.12%	163B
PFIZER, INC.	-5.00%	153B
SANOFI	-1.39%	118B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

AstraZeneca : Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria

EPS Revisions